Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;33(5):463-468.
doi: 10.1016/j.joa.2017.07.004. Epub 2017 Aug 31.

Cardiac troponin T as a predictor of cardiac death in patients with left ventricular dysfunction

Affiliations

Cardiac troponin T as a predictor of cardiac death in patients with left ventricular dysfunction

Hironori Nakamura et al. J Arrhythm. 2017 Oct.

Abstract

Background: Cardiac troponin T (cTnT) has been reported to be associated with cardiac mortality. In the present study, we evaluated the role of routine assessment of cTnT as a predictor of future cardiac death in patients with left ventricular (LV) dysfunction.

Methods: Patients who were eligible for prophylactic implantable cardioverter defibrillator (ICD) were included from cardiac catheterization database. Inclusion criteria were patients with LV ejection fraction of ≤ 35% and with New York Heart Association (NYHA) ≥class II. Exclusion criteria were patients with acute coronary syndrome, ICD for secondary prevention, NYHA class IV, and lack of data. The final study patients were divided into the following three groups in accordance with two quartile points of serum cTnT levels: low cTnT, intermediate cTnT, and high cTnT groups. The primary endpoint of this study was cardiac death.

Results: A total of 70 patients were included (mean age, 62±13 years; male individuals, 56; ischemic, 36; and non-ischemic, 34). During the observation period of 2.2 years, cardiac death was observed in 17 patients (fatal arrhythmic event, 9; heart failure, 7; myocardial infarction, 1). In the Kaplan-Meier analysis, the high cTnT group showed the highest risk among all the groups (p<0.001). Even in sub-analyses for ischemic and non-ischemic patients, the results were the same, and the high cTnT group showed the highest event rate (p<0.05). In contrast, no cardiac death was observed in the low cTnT group.

Conclusion: The cTnT levels in a stable state were associated with cardiac death in patients with LV dysfunction, even in those with non-ischemic diseases.

Keywords: Cardiac death; Cardiac troponin T; Left ventricular dysfunction; Sudden death.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier estimates of prognoses in the three patient groups with different cTnT levels. This figure shows Kaplan–Meier estimates of prognoses in patient groups with low, intermediate, and high cTnT levels. Panel A presents the results for all patients with cardiac death. The event rate was higher in the high cTnT group than in the other groups. Panel B presents the sub-analysis data for IHD patients. The event rate was higher in the high cTnT group than in the other groups, and no event was observed in the low and intermediate cTnT groups. Panel C presents the sub-analysis data for non-IHD patients. The event rate was higher in the high cTnT group than in the other groups. IHD=ischemic heart disease, cTnT=cardiac troponin T, HR=hazard ratio, 95% CI=95% confidential interval.

Similar articles

Cited by

References

    1. Yancy C.W., Jessup M., Bozkurt B. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:240–327. - PubMed
    1. Ponikowski P., Voors A.A., Anker S.D. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;2016(37):2129–2200. - PubMed
    1. Moss A.J., Hall W.J., Cannom D.S. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–1940. - PubMed
    1. Moss A.J., Zareba W., Hall W.J. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883. - PubMed
    1. Bardy G.H., Lee K.L., Mark D.B. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237. - PubMed